Literature DB >> 15514012

Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness.

Shaul Beyth1, Zipora Borovsky, Dror Mevorach, Meir Liebergall, Zulma Gazit, Hadi Aslan, Eithan Galun, Jacob Rachmilewitz.   

Abstract

Infusion of either embryonic or mesenchymal stem cells prolongs the survival of organ transplants derived from stem cell donors and prevents graft-versus-host-disease (GVHD). An in-depth mechanistic understanding of this tolerization phenomenon could lead to novel cell-based therapies for transplantation. Here we demonstrate that while human mesenchymal stem cells (hMSCs) can promote superantigen-induced activation of purified T cells, addition of antigen-presenting cells (APCs; either monocytes or dendritic cells) to the cultures inhibits the T-cell responses. This contact- and dose-dependent inhibition is accompanied by secretion of large quantities of interleukin (IL)-10 and aberrant APC maturation, which can be partially overridden by the addition of factors that promote APC maturation (ie, lipopolysaccharide [LPS] or anti-CD40 monoclonal antibody [mAb]). Thus, our data support an immunoregulatory mechanism wherein hMSCs inhibit T cells indirectly by contact-dependent induction of regulatory APCs with T-cell-suppressive properties. Our data may reveal a physiologic phenomenon whereby the development of a distinct APC population is regulated by the tissue's cellular microenvironment.

Entities:  

Mesh:

Year:  2004        PMID: 15514012     DOI: 10.1182/blood-2004-07-2921

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  328 in total

1.  Immune modulation of co-transplantation mesenchymal stem cells with islet on T and dendritic cells.

Authors:  F R Li; X G Wang; C Y Deng; H Qi; L L Ren; H X Zhou
Journal:  Clin Exp Immunol       Date:  2010-05-07       Impact factor: 4.330

2.  Allogeneic mesenchymal stem cells do not protect NZBxNZW F1 mice from developing lupus disease.

Authors:  M Youd; C Blickarz; L Woodworth; T Touzjian; A Edling; J Tedstone; M Ruzek; R Tubo; J Kaplan; T Lodie
Journal:  Clin Exp Immunol       Date:  2010-04-29       Impact factor: 4.330

Review 3.  Dendritic cells and regulation of graft-versus-host disease and graft-versus-leukemia activity.

Authors:  Elizabeth O Stenger; Hēth R Turnquist; Markus Y Mapara; Angus W Thomson
Journal:  Blood       Date:  2012-03-07       Impact factor: 22.113

Review 4.  Mesenchymal stromal cells for cell therapy: besides supporting hematopoiesis.

Authors:  Lei Hao; Huiqin Sun; Jin Wang; Tao Wang; Mingke Wang; Zhongmin Zou
Journal:  Int J Hematol       Date:  2011-12-20       Impact factor: 2.490

Review 5.  Recent progress toward understanding the physiological function of bone marrow mesenchymal stem cells.

Authors:  Chao Shi
Journal:  Immunology       Date:  2012-06       Impact factor: 7.397

Review 6.  Cardiac cell therapy: boosting mesenchymal stem cells effects.

Authors:  E Samper; A Diez-Juan; J A Montero; P Sepúlveda
Journal:  Stem Cell Rev Rep       Date:  2013-06       Impact factor: 5.739

7.  Mesenchymal stem cells impair in vivo T-cell priming by dendritic cells.

Authors:  Sabrina Chiesa; Silvia Morbelli; Sara Morando; Michela Massollo; Cecilia Marini; Arinna Bertoni; Francesco Frassoni; Soraya Tabera Bartolomé; Gianmario Sambuceti; Elisabetta Traggiai; Antonio Uccelli
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-29       Impact factor: 11.205

Review 8.  Activity of mesenchymal stem cells in therapies for chronic skin wound healing.

Authors:  Austin Nuschke
Journal:  Organogenesis       Date:  2013-12-10       Impact factor: 2.500

9.  Intranasal delivery of central nervous system-retargeted human mesenchymal stromal cells prolongs treatment efficacy of experimental autoimmune encephalomyelitis.

Authors:  Moa Fransson; Elena Piras; Hao Wang; Joachim Burman; Ida Duprez; Robert A Harris; Katarina LeBlanc; Peetra U Magnusson; Eva Brittebo; Angelica S I Loskog
Journal:  Immunology       Date:  2014-07       Impact factor: 7.397

10.  The pro-inflammatory peptide LL-37 promotes ovarian tumor progression through recruitment of multipotent mesenchymal stromal cells.

Authors:  Seth B Coffelt; Frank C Marini; Keri Watson; Kevin J Zwezdaryk; Jennifer L Dembinski; Heather L LaMarca; Suzanne L Tomchuck; Kerstin Honer zu Bentrup; Elizabeth S Danka; Sarah L Henkle; Aline B Scandurro
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-20       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.